HIMS logo

HIMSHims & Hers Health Inc

$29.99
$3.35
(12.49%)
Today
Closed $30.17
$0.18
(0.60%)
Overnight
Updated: 11:49 PM EDT
EarningsAug 10
Mkt Cap$6.21B
Vol22.98M
News
all
press releases
HIMS Stock Set To Test A Crucial Resistance – Is Retail Expecting A Breakout?
In April, the stock faced resistance near $30 and saw selling pressure in the following weeks.  
Stocktwits
News Placeholder
More News
News Placeholder
Doximity (DOCS) Up 11.2% Since Last Earnings Report: Can It Continue?
Doximity (DOCS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
Hims & Hers Health, Inc. (HIMS) closed at $27.71 in the latest trading session, marking a -4.38% move from the prior day.
Zacks
News Placeholder
OMCL vs. HIMS: Which Stock Is the Better Value Option?
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Zacks
News Placeholder
Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue?
Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks
News Placeholder
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now?
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now...
Yahoo! Finance: News
News Placeholder
Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock
Hims & Hers Health (NYSE: HIMS) is trying to turn GLP-1 demand, subscriber growth, and international expansion into a much larger healthcare platform. The stock has dropped sharply, margins are under pressure, and valuation still looks demanding, but the long-term upside coul...
Nasdaq News: Markets
News Placeholder
TD Cowen Raises GLP-1 Sales Forecast To $150B By 2030 – Industry Leaders LLY, NVO To Remain Dominant
TD Cowen expects around 59 million patients worldwide to be using GLP-1 therapies by the end of the decade, up sharply from its previous estimate of 46 million.
Stocktwits
News Placeholder
HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWatchers Turn Up The Heat
Competition is intensifying after WeightWatchers' Med+ program became available through LillyDirect.
Stocktwits
<
1
2
...
>